ABBV Ticker Curator

• Elahere oncology win: Phase 2 data shows 62.7% ORR in FRα-high platinum-sensitive ovarian cancer, 81% progression-free, consistent safety.
• Haisco...

Minimal ABBV impact from CollPlant's termination of their 2021 development deal for rhCollagen-based aesthetics fillers.

• Agreement end: Allergan...

Strategic licensing bet: AbbVie secures exclusive global rights (ex-China/HK/Macau) to Haisco's preclinical/Phase 1 pain assets, including...

• Termination by AbbVie: Allergan Industrie SAS notified CollPlant on April 9, 2026, of ending the February 2021 rhCollagen-based dermal/soft tissue...

Breakthrough Phase II data positions Elahere for platinum-sensitive ovarian cancer (PSOC) growth:

• 62.7% confirmed ORR in FRα ≥50% subgroup (62.4%...

AbbVie's bold non-opioid play: $30M upfront + up to $715M milestones for ex-China rights to HSK55718 (Ph1 IV) and HSK51155 (preclinical oral) NaV1.8...

Neuroscience franchise set to meaningfully aid Q1 top-line amid immunology dominance:

• Expects $2.8B revenues, consensus $2.79B (+22% YoY)
• Driven...

AbbVie partners with Haisco for pain therapy development, with potential for up to $715 million in milestones plus tiered royalties. This deal highlights the company's commitment to enhancing its product portfolio.

• Deal Ends: CollPlant terminated $26M AbbVie (Allergan) development agreement for medical aesthetics fillers after 60-day notice.
• Pipeline Hit:...

Key Deal Breakdown:

• Upfront + Milestones: Haisco gets $30M upfront and up to $715M in dev/reg/commercial milestones, plus tiered royalties.
  -...

ELAHERE Phase 2 Data in PSOC

• 🔥 62.7% ORR Achieved: Phase 2 IMGN853-0420 trial showed 62.7% objective response rate for mirvetuximab...

Strategic BD win: AbbVie gains exclusive global rights (ex-China) to Haisco's preclinical-to-Phase 1 pain compounds, adding neuroscience depth.
-...

• PICCOLO breakthrough: Phase 2 trial hits 51.9% ORR (vs 16.9% prior) and 27.17-month median OS (vs 19.35) in platinum-sensitive ovarian cancer.
  -...

Key Q4 2025 trim by major investor:

• Sumitomo Mitsui Trust Group reduced AbbVie stake by 3.6%, selling 153,226 shares per 13F filing.
• Now holds...

Key Ph2 highlights for AbbVie's ELAHERE in platinum-sensitive ovarian cancer (PSOC):

• 62.7% confirmed ORR (FRα ≥50% subgroup) with combo +...

Robust efficacy across PSOC trials boosts AbbVie's pipeline:

• IMGN853-0420 combo: 62.7% ORR with carboplatin in ≥50% FRα patients; consistent...

Key deal highlights for AbbVie's pain pipeline:

• Exclusive global rights (ex-China, HK, Macau) to develop Nav1.8 inhibitors HSK55718 (Phase I IV) and...

• Robeco trimmed its ABBV stake by 3.4% in Q4, selling 112,895 shares; now holds 3.21M shares (~$734M, 11th-largest position)
• Mixed 13F flows:...

Earnings Guidance & Analyst Views

• 🔥 AbbVie Lowers 2026 Outlook: AbbVie lowered its full-year 2026 adjusted diluted EPS guidance to...

GLP-1 market explodes to $73.4B in 2026 (+16.8% YoY), with Eli Lilly at 57% share (Mounjaro/Zepbound $36.5B FY2025) and Novo Nordisk 31.5% (~$33B).

-...